Tumor marker for urothelial carcinoma

Details Tumor marker for urothelial carcinoma Tumor marker for urothelial carcinoma

2008-01-29

2008-01-29

Foley, Shanon (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S004000, C435S007230

Reexamination Certificate

active

07323312

ABSTRACT:
This invention relates to a method for detecting urothelial carcinoma using an antibody that specifically reacts with a calreticulin protein or a fragment thereof and immunoassaying a calreticulin protein in a sample.

REFERENCES:
patent: 6596690 (2003-07-01), Tosato et al.
patent: 2003/0039970 (2003-02-01), Wang et al.
patent: WO 00/20577 (2000-04-01), None
patent: WO 02/06327 (2002-01-01), None
Karl-Heinz Krause and Marek Michalak, Calreticulin Cell, vol. 88, 439-443, Feb. 21, 1997, Copyright.
Marek Michalak 1, Elaine F. Corbett, Nasrin Mesaeli, Kimitoshi Nakamura and Michal Opas Calreticulin : one protein, one gene, many functions, Biochem. J. (1999) 344, 281±292 (.
Alaiya A, Roblick U, Egevad L, Carlsson A, Franzen B, Volz D, Huwendiek S, Linder S, Auer GPolypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol. 2000;21(1):1-9.
Ghil-Suk Yoon, Hojung Lee, Yusun Jung, Eunsil Yu, Hee-Bom Moon, Kyuyoung Song, and Inchul Lee, Nuclear Matrix of Calreticulin in Hepatocellular Carcinoma. Cancer Research 60, 1117-1120, Feb. 15, 2000.
Conway EM, Liu L, Nowakowski B, Steiner-Mosonyi M, Ribeiro SP, Michalak M Heat shock-sensitive expression of calreticulin. In vitro and in vivo up-regulation. J. Biol Chem. Jul. 14, 1995;270(28):17011-6.
Tockman MS, Gupta Pk, Pressman NJ, Mulshine JL. Considerations in bringing a cancer biomarker to clinical application. Cancer Res. May 1, 1992;52(9 Suppl):2711s-2718s.
Pannek J, Rittenhouse HG, Evans CL, Finlay JA, Bruzek DJ, Cox JL, Chan DW, Subong EN, Partin AW, Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection . . . Urology. Nov. 1997;50(5):71.
Yoon et al., Cancer Research, vol. 60, pp. 1117-1120 (Feb. 15, 2000).
Yu et al., Electrophoresis, vol. 21, pp. 3058-3068 (2000).
Bini et al., Electrophoresis, vol. 18, pp. 2832-2841 (1997).
Celis et al., Electrophoresis, vol. 20, pp. 300-309 (1999).
Celis et al., “Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities”Electrophoresis, 20, pp. 355-361 (1999).
Syrigos et al., “Use of Monoclonal Antibodies for the Diagnosis and Treatment of Bladder Cancer”Hybridoma, vol. 18, No. 3 (1999).
Konety et al., “Urine Based Markers of Urological Malignancy”The Journal of Urology, vol. 165, pp. 600-611 (2001).
Kageyama et al., “Identification by Proteomic Analysis of Calreticulin as a Marker for Bladder Cancer and Evaluation of the Diagnostic Accuracy of Its Detection in Urine”Clinical Chemistry,50:5, pp. 857-866 (2004).

Affiliated with

Also associated with

Rating

Tumor marker for urothelial carcinoma does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor marker for urothelial carcinoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor marker for urothelial carcinoma will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2766707